Anagani Kanaka Durga Bhavani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anagani Kanaka Durga Bhavani has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- René Grée
Univ Rennes, CNRS, ISCR (Institut des Sciences Chimiques de Rennes), UMR 6226, F-35000 Rennes, Francehttps://ror.org/015m7wh34https://www.isni.org/isni
2 shared publications Anwita Mudiraj
Department of Biotechnology and Bioinformatics, School of Life Sciences, University of Hyderabad, Hyderabad, 500046, India
1 shared publicationAppala Venkata Ramana Murthy
Chemveda Life Sciences India Pvt. Ltd., #B-11/1, IDA Uppal, Hyderabad 500039, Telangana, India; Jawaharlal Nehru Technological University Hyderabad, Kukatpally, Hyderabad 500 085, Telangana, India
1 shared publication- Blandine Baratte
Sorbonne Université, CNRS FR2424, Plateforme de criblage KISSf (Kinase Inhibitor Specialized Screening facility) Station Biologique, Place Georges Teissier, CS90074, 29688 Roscoff Cedex, France
1 shared publication Chada Raji Reddy
Department of Organic Synthesis & Process Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India
1 shared publication- Chada Raji Reddy
Department of Organic Synthesis & Process Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad - 500007, India
1 shared publication
Latest Publications
- Open Access
Structure Activity Relationship Studies around DB18, a Potent and Selective Inhibitor of CLK Kinases
Three series of our lead CLK1 inhibitor DB18 have been designed, synthetized and tested against CLKs and DYRK1A kinases. Their cytotoxicity was subsequently measured on seven representative cancer cell lines. Guided by docking experiments, we focused on the less constrained part of the scaffold, and showed that drastically different substituents can be tolerated here. This work ended with the discovery of another promising derivative 12g, with IC50 = 0.004 µM in the inhibition of HsCLK1 and IC50 = 3.94 µM for the inhibition of HsDYRK1A. The SAR results are discussed in the light of extensive molecular modeling analyses. Finally, a kinome scan (463 human kinases) confirmed the outstanding selectivity of our lead compound DB18, suggesting that this scaffold is of prominent interest for selective CLK inhibitors. Altogether, these results pave the way for the development of inhibitors with novel selectivities in this family of kinases.
Open AccessStructure Activity Relationship Studies around DB18, a Potent and Selective Inhibitor of CLK Kinases
Three series of our lead CLK1 inhibitor DB18 have been designed, synthetized and tested against CLKs and DYRK1A kinases. Their cytotoxicity was subsequently measured on seven representative cancer cell lines. Guided by docking experiments, we focused on the less constrained part of the scaffold, and showed that drastically different substituents can be tolerated here. This work ended with the discovery of another promising derivative 12g, with IC50 = 0.004 µM in the inhibition of HsCLK1 and IC50 = 3.94 µM for the inhibition of HsDYRK1A. The SAR results are discussed in the light of extensive molecular modeling analyses. Finally, a kinome scan (463 human kinases) confirmed the outstanding selectivity of our lead compound DB18, suggesting that this scaffold is of prominent interest for selective CLK inhibitors. Altogether, these results pave the way for the development of inhibitors with novel selectivities in this family of kinases.
- 20 June 2022
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 69, 116851
Discovery of potent dual ligands for dopamine D4 and σ1 receptors
- 20 June 2022
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 69, 116851
Discovery of potent dual ligands for dopamine D4 and σ1 receptors
- 1 August 2018
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 156, 43-52
Synthesis of pyrazolo[3,4-d]pyrimidin-4(5H)-ones tethered to 1,2,3-triazoles and their evaluation as potential anticancer agents
- 1 August 2018
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 156, 43-52
Synthesis of pyrazolo[3,4-d]pyrimidin-4(5H)-ones tethered to 1,2,3-triazoles and their evaluation as potential anticancer agents